Use and Abuse of Religious Exemptions from School Immunization Requirements
Total Page:16
File Type:pdf, Size:1020Kb

Load more
Recommended publications
-
Program Evaluation Key Outcomes and Addressing Remaining
Vaccine 31S (2013) J73–J78 Contents lists available at ScienceDirect Vaccine jou rnal homepage: www.elsevier.com/locate/vaccine Key outcomes and addressing remaining challenges—Perspectives from a final ଝ evaluation of the China GAVI project a,1 a,1 a,1 a,1 b c Weizhong Yang , Xiaofeng Liang , Fuqiang Cui , Li Li , Stephen C. Hadler , Yvan J. Hutin , d a,∗ Mark Kane , Yu Wang a Chinese Center for Disease Control and Prevention, Beijing, China b Centers for Disease Control and Prevention, Atlanta, USA c Europe Center for Disease Control and Prevention, Stockholm, Sweden d Mercer Island, Washington, USA a r t a b i c s t l r e i n f o a c t Article history: During the China GAVI project, implemented between 2002 and 2010, more than 25 million children Received 6 June 2012 received hepatitis B vaccine with the support of project, and the vaccine proved to be safe and effective. Received in revised form 24 July 2012 With careful consideration for project savings, China and GAVI continually adjusted the budget, addi- Accepted 24 September 2012 tionally allowing the project to spend operational funds to support demonstration projects to improve timely birth dose (TBD), conduct training of EPI staff, and to monitor the project impact. Results from the final evaluation indicated the achievement of key outcomes. As a result of government co-investment, Keywords: human resources at county level engaged in hepatitis B vaccination increased from 29 per county on GAVI Project average in 2002 to 66 in 2009. All project counties funded by the GAVI project use auto-disable syringes Outcomes for hepatitis B vaccination and other vaccines. -
A Risk/Reward View of Vaccines
A Risk/Reward View of Vaccines Addressing the confusion and presenting a different approach to the vaccine question as it relates to the frum community For those interested in minimizing the growing Machlokes Ver. 11/14//2019 (latest version at www.rodefshalom613.org) email [email protected] or leave a message at (414) 751-0001 with any corrections DRAFT Table of Contents Page Time to Read Introduction 4-9 5 Min. Main Presentation 10-41 15 min Critical Update as of 4/9/19 40 Appendix A - Wakefield: Defended/Exonerated 42 Appendix B - Scientists and Doctors on Vaccine Harm 43-44 Appendix C - Literature about Vaccine Harm 45-46 Appendix C1 - Vaccines and SIDS 47-48 Appendix C2 - Vaccines, Autism, and Under 5 Mortality 49 Appendix D - Ingredients in Vaccines 50 Appendix D1 - The Difference Between Vaccines and Chemical Drugs 51 Appendix D2 - Some Biologic (Vaccine) Recalls 52-54 Appendix E - What about Herd Immunity? 55-56 Appendix F - But They Can't All Be Wrong - Can They? 57 Appendix G - Is the CDC Lying? 58-59 Appendix H - How Profitable is the Vaccine Industry? 60-62 Appendix H1 - Conflicts of Interest in the Vaccine Industry 63 Appendix I - Dr. Paul Offit on Metziza B'peh and Bris Milah 64-65 Appendix J - Why Don’t Doctors See This? 66-68 Appendix K - Specialist vs General Practitioner - Who do you go to? 69 Appendix L - Rav Osher Weiss Psak - Comprehensive Review 70-79 Appendix M - Alternate Shailos for a Posek 80 Appendix N - An Open Letter to Poskim who demand vaccination 81-84 2 Table of Contents (cont) Page Time to Read Appendix O - Religious Exemption - Do you really want to give that up? 85-86 Appendix P - Ethical Argument 87-88 Appendix Q - Books - Is it responsible to Pasken without even reading one of these? 89 Appendix R - Smallpox and Polio 90-91 92 Appendix S - Flu Vaccines 93 Appendix T - Additional Resources and Interesting Articles 94 Appendix U - A critical lesson from the Ukraine 95 Follow-up Opportunities 96 3 -An important NOTICE for you- This presentation is not pro-vaccine or anti-vaccine. -
UNHCR COVID-19 Global Emergency Response
GLOBAL COVID-19 EMERGENCY RESPONSE 17 February 2021 UNHCR COVID-19 Preparedness and Response Highlights COVID-19 update ■ UNHCR and Gavi, the Vaccine Alliance, signed a Memorandum of Over 46,000 Understanding (MoU) on 03 February 2020, with the overall goal of ensuring reported cases refugees and other forcibly displaced can access vaccines on par with of COVID-19 nationals. The MoU also looks at expanding coverage and quality of among forcibly displaced people immunization services, promoting equity in access and uptake of vaccines, and strengthening health systems at community and primary care level. across 103 countries ■ Jordan has become one of the world’s first countries to start COVID-19 vaccinations for refugees, including vaccinations in Za’atari refugee camp on 15 February. UNHCR has been working with the Jordanian government to increase of vaccinate refugees and provide critical health, sanitation, hygiene and logistical some 7,500 cases compared support. UNHCR appeals to all countries to follow suit and include refugees in to the previous their national vaccination drives in line with COVAX allocation principles. reporting period ■ In 2020, 39.4 million persons of concern received COVID-19 assistance (numbers as of 08 February including access to protection services, shelter, health, and education. This 2021) includes over 8.5 million individuals who received cash assistance. ■ Despite an estimated 1.44 million refugees in urgent need of resettlement globally, less than 23,000 were resettled through UNHCR last year. These are the lowest refugee resettlement numbers UNHCR has witnessed in almost two decades. The drop stems from low quotas put forward by states, as well as the impact of COVID-19, which delayed departures and programmes. -
Vaccine Hesitancy
WHY CHILDREN WORKSHOP ON IMMUNIZATIONS ARE NOT VACCINATED? VACCINE HESITANCY José Esparza MD, PhD - Adjunct Professor, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA - Robert Koch Fellow, Robert Koch Institute, Berlin, Germany - Senior Advisor, Global Virus Network, Baltimore, MD, USA. Formerly: - Bill & Melinda Gates Foundation, Seattle, WA, USA - World Health Organization, Geneva, Switzerland The value of vaccination “The impact of vaccination on the health of the world’s people is hard to exaggerate. With the exception of safe water, no other modality has had such a major effect on mortality reduction and population growth” Stanley Plotkin (2013) VACCINES VAILABLE TO PROTECT AGAINST MORE DISEASES (US) BASIC VACCINES RECOMMENDED BY WHO For all: BCG, hepatitis B, polio, DTP, Hib, Pneumococcal (conjugated), rotavirus, measles, rubella, HPV. For certain regions: Japanese encephalitis, yellow fever, tick-borne encephalitis. For some high-risk populations: typhoid, cholera, meningococcal, hepatitis A, rabies. For certain immunization programs: mumps, influenza Vaccines save millions of lives annually, worldwide WHAT THE WORLD HAS ACHIEVED: 40 YEARS OF INCREASING REACH OF BASIC VACCINES “Bill Gates Chart” 17 M GAVI 5.6 M 4.2 M Today (ca 2015): <5% of children in GAVI countries fully immunised with the 11 WHO- recommended vaccines Seth Berkley (GAVI) The goal: 50% of children in GAVI countries fully immunised by 2020 Seth Berkley (GAVI) The current world immunization efforts are achieving: • Equity between high and low-income countries • Bringing the power of vaccines to even the world’s poorest countries • Reducing morbidity and mortality in developing countries • Eliminating and eradicating disease WHY CHILDREN ARE NOT VACCINATED? •Vaccines are not available •Deficient health care systems •Poverty •Vaccine hesitancy (reticencia a la vacunacion) VACCINE HESITANCE: WHO DEFINITION “Vaccine hesitancy refers to delay in acceptance or refusal of vaccines despite availability of vaccination services. -
CONGRESSIONAL RECORD—HOUSE June 23, 2005 Please Read This Article
June 23, 2005 CONGRESSIONAL RECORD—HOUSE 13935 why rescind support for highly re- rifice to be remembered for the good (Mr. WELDON) believe, that mercury spected objective news programs like and honorable actions he was doing in should be taken out of all childhood the NewsHour with Jim Lehrer and Iraq. vaccines and in fact all vaccines. Frontline? His service showed the true American We need to ask ourselves one simple Why cripple excellent radio stations spirit. While the Lapinskis lost their question: What is right? The answer I like WUKY and WEKU in my district, son, they know that he died preserving think is very clear. Get mercury out of jeopardizing shows like Morning Edi- and fighting for democracy. all vaccinations. tion and All Things Considered? Mr. Speaker, I ask all Americans to In reality the answer that is given by Why indeed? I cannot answer such join me in honoring a true American far too many officials in our govern- questions. The very notion of turning hero. ment, health agencies and some Mem- bers of Congress, sorry, we cannot help away from the future of public broad- f casting is preposterous. I am fearful you, and the need to protect the phar- ORDER OF BUSINESS this is an administration effort to ei- maceutical industry is so great, we ther censor public broadcasters or in- Mr. BURTON of Indiana. Mr. Speak- cannot do much about it. timidate them into favorably reporting er, I ask unanimous consent to claim b 1745 the time of the gentleman from Min- on the current administration. -
Congressional Record—House H5074
H5074 CONGRESSIONAL RECORD — HOUSE June 23, 2005 As Thomas Jefferson once said, MERCURY AND AUTISM them while at the same time changing Whenever people are well informed, The SPEAKER pro tempore. Under a the Vaccine Injury Compensation Fund they can be trusted with their own gov- previous order of the House, the gen- in a way that will protect these fami- ernment. tleman from Indiana (Mr. BURTON) is lies and help those who have been dam- Maintaining our commitment to pub- recognized for 5 minutes. aged, but so far we have gotten abso- lic broadcasting will help keep the very Mr. BURTON of Indiana. Mr. Speak- lutely nowhere with them; and it is people who elect us well informed, and er, I have been down here a lot talking something I think we need to continue in doing so, help to promote the integ- about autism over the years and my to work on. rity and proper functioning of this very committee had many hearings on the Just recently, there was an article body itself. issue of autism. My grandson became that was published in a magazine I nor- I applaud the Members of this body autistic after receiving 9 shots in one mally do not read. It is called Rolling who rose to the defense of public broad- day, 7 of which contained mercury, in a Stone, but this article was brought to casting earlier today by voting to re- product called thimerosal. And he is my attention, and I think everybody in store funding to a cherished American doing better but it has been a very dif- this body ought to read that article. -
Predictors of Vaccine Hesitancy: Implications for COVID-19 Public Health Messaging
International Journal of Environmental Research and Public Health Review Predictors of Vaccine Hesitancy: Implications for COVID-19 Public Health Messaging Amanda Hudson 1,2,* and William J. Montelpare 3 1 Department of Mental Health and Addiction, Health PEI, Charlottetown, PE C1C 1M3, Canada 2 Department of Health Management, University of Prince Edward Island, Charlottetown, PE C1A 4P3, Canada 3 Department of Applied Human Sciences, University of Prince Edward Island, Charlottetown, PE C1A 4P3, Canada; [email protected] * Correspondence: [email protected] Abstract: Objectives: Successful immunization programs require strategic communication to increase confidence among individuals who are vaccine-hesitant. This paper reviews research on determinants of vaccine hesitancy with the objective of informing public health responses to COVID-19. Method: A literature review was conducted using a broad search strategy. Articles were included if they were published in English and relevant to the topic of demographic and individual factors associated with vaccine hesitancy. Results and Discussion: Demographic determinants of vaccine hesitancy that emerged in the literature review were age, income, educational attainment, health literacy, rurality, and parental status. Individual difference factors included mistrust in authority, disgust sensitivity, and risk aversion. Conclusion: Meeting target immunization rates will require robust public health campaigns that speak to individuals who are vaccine-hesitant in their attitudes and behaviours. Based on the assortment of demographic and individual difference factors that contribute Citation: Hudson, A.; Montelpare, to vaccine hesitancy, public health communications must pursue a range of strategies to increase W.J. Predictors of Vaccine Hesitancy: public confidence in available COVID-19 vaccines. Implications for COVID-19 Public Health Messaging. -
Environmental Health Issue
FIFTH EDITION 2006, Volume 45 R5 Environmental Health and Autism In thIs Issue: Time To GeT a Grip By martha r. Herbert, m.D., ph.D. Beyond Behavior—Biomedical Diagnoses in Autism spectrum Disorders By Margaret L. Bauman, M.D. transforming the Public Debate on neurotoxicants By Elise Miller, M.Ed. ADVERTISEMENT ADVERTISEMENT Autism does not have to be a life sentence You’re not about to give up on your child. Neither Are We. Since , the Autism Treatment Center of America™ has provided innovative training programs for parents and professionals caringifor children challenged by Autism Spectrum Disorders and related developmental difficulties. • Practical Tools • Powerful Results • Limitless Hope c Help your child improve in all areas of over p learning, development, communication and hoto skill acquisition. : © W I Join us for our internationally-acclaimed ll T ERR Son-Rise Program® Start-Up, a y comprehensive weeklong training program for parents and professionals. We don’t put limits on the possibilities for your child. Free 25-Minute Initial Call 877-766-7473 We’ll give you the keys to unlock their world. HOME OF THE SON-RISE PROGRAM® SINCE 1983 South Undermountain Road Sheffield, MA - USA Telephone: -- • E-mail: [email protected] www.autismtreatment.com Copyright © 2006 by The Option Institute & Fellowship. All rights reserved. 02.06-6 CONTENTS December 2006 page 18 SpOTlIGHT Time to Get A Grip By marTHa r. HerBerT, m.D., pH.D. Does an environmental role in autism make sense? How do we decide? And if environment is involved in autism, what do we do about it? These are challenging questions. -
Vaccine Adjuvants: from 1920 to 2015 and Beyond
Vaccines 2015, 3, 320-343; doi:10.3390/vaccines3020320 OPEN ACCESS vaccines ISSN 2076-393X www.mdpi.com/journal/vaccines Review Vaccine Adjuvants: from 1920 to 2015 and Beyond Alberta Di Pasquale 1,*, Scott Preiss 1, Fernanda Tavares Da Silva 1 and Nathalie Garçon 2 1 GSK Vaccines, Avenue Fleming, 1300 Wavre, Belgium; E-Mails: [email protected] (S.P.); [email protected] (F.T.D.S.) 2 Bioaster, 321 Avenue Jean Jaurès, 6700 Lyon, France; E-Mail: [email protected] * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +32-10-85-3573. Academic Editor: Diane M. Harper Received: 23 February 2015 / Accepted: 9 April 2015 / Published: 16 April 2015 Abstract: The concept of stimulating the body’s immune response is the basis underlying vaccination. Vaccines act by initiating the innate immune response and activating antigen presenting cells (APCs), thereby inducing a protective adaptive immune response to a pathogen antigen. Adjuvants are substances added to vaccines to enhance the immunogenicity of highly purified antigens that have insufficient immunostimulatory capabilities, and have been used in human vaccines for more than 90 years. While early adjuvants (aluminum, oil-in-water emulsions) were used empirically, rapidly increasing knowledge on how the immune system interacts with pathogens means that there is increased understanding of the role of adjuvants and how the formulation of modern vaccines can be better tailored towards the desired clinical benefit. Continuing safety evaluation of licensed vaccines containing adjuvants/adjuvant systems suggests that their individual benefit-risk profile remains favorable. -
COVID-19: Mechanisms of Vaccination and Immunity
Review COVID-19: Mechanisms of Vaccination and Immunity Daniel E. Speiser 1,* and Martin F. Bachmann 2,3,4,* 1 Department of Oncology, University Hospital and University of Lausanne, 1066 Lausanne, Switzerland 2 International Immunology Centre, Anhui Agricultural University, Hefei 230036, China 3 Department of Rheumatology, Immunology and Allergology, Inselspital, University of Bern, 3010 Bern, Switzerland 4 Department of BioMedical Research, University of Bern, 3008 Bern, Switzerland * Correspondence: [email protected] (D.E.S.); [email protected] (M.F.B.) Received: 2 July 2020; Accepted: 20 July 2020; Published: 22 July 2020 Abstract: Vaccines are needed to protect from SARS-CoV-2, the virus causing COVID-19. Vaccines that induce large quantities of high affinity virus-neutralizing antibodies may optimally prevent infection and avoid unfavorable effects. Vaccination trials require precise clinical management, complemented with detailed evaluation of safety and immune responses. Here, we review the pros and cons of available vaccine platforms and options to accelerate vaccine development towards the safe immunization of the world’s population against SARS-CoV-2. Favorable vaccines, used in well-designed vaccination strategies, may be critical for limiting harm and promoting trust and a long-term return to normal public life and economy. Keywords: SARS-CoV-2; COVID-19; nucleic acid tests; serology; vaccination; immunity 1. Introduction The COVID-19 pandemic holds great challenges for which the world is only partially prepared [1]. SARS-CoV-2 combines serious pathogenicity with high infectivity. The latter is enhanced by the fact that asymptomatic and pre-symptomatic individuals can transmit the virus, in contrast to SARS-CoV-1 and MERS-CoV, which were transmitted by symptomatic patients and could be contained more efficiently [2,3]. -
Why Anti-Vaccine Claims About NVICP Cases Are Wrong
Minnesota Journal of Law, Science & Technology Volume 20 Issue 1 Article 11 8-7-2019 Using and Misusing Legal Decisions: Why Anti-Vaccine Claims about NVICP Cases Are Wrong Dorit Rubinstein Reiss UC Hastings College of Law Rachel Heap Follow this and additional works at: https://scholarship.law.umn.edu/mjlst Part of the Administrative Law Commons, Health Law and Policy Commons, and the Other Medicine and Health Sciences Commons Recommended Citation Dorit Rubinstein Reiss & Rachel Heap, Using and Misusing Legal Decisions: Why Anti-Vaccine Claims about NVICP Cases Are Wrong, 20 MINN. J.L. SCI. & TECH. 191 (2018). Available at: https://scholarship.law.umn.edu/mjlst/vol20/iss1/11 The Minnesota Journal of Law, Science & Technology is published by the University of Minnesota Libraries Publishing. Using and Misusing Legal Decisions: Why Anti-Vaccine Claims about NVICP Cases Are Wrong Dorit Rubinstein Reiss*and Rachel Heap† Abstract The question of whether vaccines cause autism spectrum disorder (autism, or ASD) has been extensively studied. Studies from different countries around the world, looking at millions of children in total, examined it and found no link. Despite this powerful evidence, the actions of a small group who fervently believe that vaccines cause autism may lead people to question the data. One tactic used to argue that vaccines cause autism is the use of compensation decisions from the National Vaccine Injury Compensation Program to claim such a link. This article demonstrates that not only does the nature of proof in the program make its decisions ill-suited to challenging the science but also that the cases used do not, in their content, support that conclusion. -
I M M U N O L O G Y Core Notes
II MM MM UU NN OO LL OO GG YY CCOORREE NNOOTTEESS MEDICAL IMMUNOLOGY 544 FALL 2011 Dr. George A. Gutman SCHOOL OF MEDICINE UNIVERSITY OF CALIFORNIA, IRVINE (Copyright) 2011 Regents of the University of California TABLE OF CONTENTS CHAPTER 1 INTRODUCTION...................................................................................... 3 CHAPTER 2 ANTIGEN/ANTIBODY INTERACTIONS ..............................................9 CHAPTER 3 ANTIBODY STRUCTURE I..................................................................17 CHAPTER 4 ANTIBODY STRUCTURE II.................................................................23 CHAPTER 5 COMPLEMENT...................................................................................... 33 CHAPTER 6 ANTIBODY GENETICS, ISOTYPES, ALLOTYPES, IDIOTYPES.....45 CHAPTER 7 CELLULAR BASIS OF ANTIBODY DIVERSITY: CLONAL SELECTION..................................................................53 CHAPTER 8 GENETIC BASIS OF ANTIBODY DIVERSITY...................................61 CHAPTER 9 IMMUNOGLOBULIN BIOSYNTHESIS ...............................................69 CHAPTER 10 BLOOD GROUPS: ABO AND Rh .........................................................77 CHAPTER 11 CELL-MEDIATED IMMUNITY AND MHC ........................................83 CHAPTER 12 CELL INTERACTIONS IN CELL MEDIATED IMMUNITY ..............91 CHAPTER 13 T-CELL/B-CELL COOPERATION IN HUMORAL IMMUNITY......105 CHAPTER 14 CELL SURFACE MARKERS OF T-CELLS, B-CELLS AND MACROPHAGES...............................................................111